AIM Vaccine's Next-Gen mRNA Shingles Vaccine Secures Clinical Approvals in Both PRC and U.S. ,mRNA Platform Advantages Shine Through
HONG KONG, May 19, 2025 /PRNewswire/ -- While global giants like Moderna and BioNTech apply mRNA technology to broader disease markets, PRC's mRNA frontrunner is keeping pace. AIM Vaccine (06660.HK), a leading domestic vaccine company, announced today that its self-developed mRNA shingles vaccine has received clinical trial approval from PRC's Center for Drug Evaluation (CDE), following its U.S. FDA clearance in March this year. The vaccine has demonstrated significantly stronger humoral and cellular immunity compared to international benchmark products.
AIM Vaccine's mRNA platform capabilities are once again in the spotlight. Fosun International Securities recently noted in a research report that AIM's mRNA shingles vaccine could challenge the existing market landscape with its potential for superior efficacy and safety.
Immunogenicity Indicators Significantly Outperform International Benchmarks
According to the announcement, preclinical trial results from third-party testing institutions demonstrate that AIM's mRNA shingles vaccine shows significantly higher specific T-cell immunity, specific IgG antibody titers, and membrane antigen fluorescent antibody (FAMA) titers compared to internationally marketed recombinant subunit control vaccines.
Furthermore, there are currently no mRNA-based shingles vaccines approved for marketing globally. According to recently published industry references, the vaccination rate for shingles vaccines among PRC's target population is less than 1%, indicating enormous growth potential.
Fosun International Securities' research report analysis mentions that as PRC's first company to establish a complete mRNA vaccine R&D system, its technological approach successfully avoids existing shingles vaccine patent barriers, creating favorable conditions for entering the global market projected to reach US$23.9 billion annually.
mRNA Platform Capabilities Continue to Lead the Industry
The competition in mRNA technology platforms between domestic and international companies has reached intensity comparable to an arms race, with infectious disease and cancer vaccines being the key battlegrounds. AIM Vaccine leads the industry through breakthrough progress in infectious disease vaccines.
Fosun International Securities' research report released in late March pointed out that AIM Vaccine holds a leading position in PRC's mRNA vaccine field, having obtained 11 clinical approvals across 6 countries, including 2 FDA approvals in the U.S. Its platform technology has been validated by favorable safety and efficacy clinical data from over 10,000 subjects. This latest approval for its mRNA shingles vaccine in PRC further highlights the company's leading position in next-generation vaccine technology and rapid commercialization potential.
Some industry observers believe that if PRC companies can continue to overcome core patents, expand indications, and deepen international cooperation, mRNA technology may become a hallmark area for PRC's biopharmaceutical industry to achieve technological leapfrogging.
In this cutting-edge field, AIM Vaccine has not only secured clinical approvals in both PRC and the U.S. for its mRNA shingles vaccine and mRNA RSV vaccine, but also has its next-generation mRNA rabies vaccine and mRNA influenza vaccine in pre-IND review and preclinical studies respectively, demonstrating the platform's strong extensibility and laying a solid foundation for sustained development and market leadership.
As analyzed by multiple investment institutions, AIM Vaccine combines innovative technology, industry leadership, and growth potential, making it a highly attractive investment choice. They remain optimistic about the company's development prospects driven by industry recovery and new products, and believe its valuation has significant upside potential.
View original content:https://www.prnewswire.com/apac/news-releases/aim-vaccines-next-gen-mrna-shingles-vaccine-secures-clinical-approvals-in-both-prc-and-us-mrna-platform-advantages-shine-through-302458430.html
SOURCE AIM Vaccine
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
an hour ago
- Bloomberg
Central Banks Have Every Reason to Keep Buying in Gold Market
Central banks have emerged as a driving force behind the record-breaking bull market for gold, and while the true scale of their buying is shrouded in mystery, nobody expects them to stop. Globally, they are accumulating roughly 80 metric tons of gold a month, worth about $8.5 billion at current prices, analysts at Goldman Sachs estimate. Most of the buying is secret, although trade data indicates China accounts for a lot of the purchases, along with other unidentified buyers via Switzerland.
Bloomberg
2 hours ago
- Bloomberg
Asian Stock Futures Buoyed by US Jobs Surprise: Markets Wrap
Asian stocks will likely draw support from US data showing the country's labor market is holding up despite concerns about risks stemming from President Donald Trump's tariff war. US shares and the dollar rose. Equity futures pointed to advances in Sydney, Tokyo and Hong Kong, after a bounce in tech giants helped the S&P 500 add 0.6%. Just days ahead of the US payrolls report, an unexpected increase in job openings buoyed sentiment, helping to offset earlier losses after the OECD said Trump's combative trade policies have tipped the world economy into a downturn, with the US among the hardest hit.
Yahoo
2 hours ago
- Yahoo
Free summer meals available for Colorado children aged 18 and younger
GRAND JUNCTION, Colo. (KREX) — On Tuesday, the Colorado Department of Education (CDE) announced that 635 summer meal sites are open throughout Colorado to provide free meals to children aged 18 and younger. Out of those 635 locations, 16 are open in Grand Junction. In Grand Junction, these locations include: Chipeta Elementary School, Dos Rios Elementary School, Pear Park Elementary School, Pomona Elementary School, Tope Elementary School, Bookcliff Middle School, Orchard Mesa Middle School, Grand Junction High School, CMU Tech, Candlewood Park, Clifton Community Center, Dual Immersion Academy School, EUREKA! Science Museum, Kimwood Park, Lincoln Park and Mesa Avenue Park. Parents, families and community members can learn more about locations and hours at No registration, identification, or proof of income or enrollment is required to access summer meals. All meals served meet USDA nutrition guidelines. The Colorado Department of Education's School Nutrition Unit, in partnership with community-based program sponsors, runs the Summer Meal Program and provided over 1.9 million meals to Colorado youth last year. The U.S. Department of Agriculture funds the program. CDE is currently working with 82 community organizations to run the 635 meal sites across the state. In rural areas, a to-go or delivery option for meals may be offered. Local schools, nonprofits, government agencies, camps, faith- or community-based organizations can join the program to provide new meal sites at any time throughout the summer. 'Many Colorado children rely on their schools for access to food, and our Summer Meals Program provides a critical resource for children and families during the summer months. We are grateful to our 83 community partners for stepping up to serve them,' said Colorado Education Commissioner Susana Córdova. In addition to the Summer Meals Program, children and teens can get free meals over the summer through the Lunch Lizard. The mobile summer food program operates across Mesa County and served its first set of children on Monday in Fruita. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
